TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapyEva Nievergall, Deborah L. White, Mark Biondo et al.|Leukemia|2016Cited by 50
Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinibChung Hoow Kok, Timothy P. Hughes, David T Yeung et al.|Blood Advances|2019Cited by 43